1. Home
  2. CUE vs RIBB Comparison

CUE vs RIBB Comparison

Compare CUE & RIBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • RIBB
  • Stock Information
  • Founded
  • CUE 2014
  • RIBB 2024
  • Country
  • CUE United States
  • RIBB Japan
  • Employees
  • CUE N/A
  • RIBB N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • RIBB
  • Sector
  • CUE Health Care
  • RIBB
  • Exchange
  • CUE Nasdaq
  • RIBB NYSE
  • Market Cap
  • CUE 60.6M
  • RIBB 64.8M
  • IPO Year
  • CUE 2018
  • RIBB 2025
  • Fundamental
  • Price
  • CUE $0.76
  • RIBB N/A
  • Analyst Decision
  • CUE Strong Buy
  • RIBB
  • Analyst Count
  • CUE 3
  • RIBB 0
  • Target Price
  • CUE $3.00
  • RIBB N/A
  • AVG Volume (30 Days)
  • CUE 206.6K
  • RIBB 52.7K
  • Earning Date
  • CUE 05-08-2025
  • RIBB 01-01-0001
  • Dividend Yield
  • CUE N/A
  • RIBB N/A
  • EPS Growth
  • CUE N/A
  • RIBB N/A
  • EPS
  • CUE N/A
  • RIBB N/A
  • Revenue
  • CUE $9,287,000.00
  • RIBB N/A
  • Revenue This Year
  • CUE N/A
  • RIBB N/A
  • Revenue Next Year
  • CUE $4.77
  • RIBB N/A
  • P/E Ratio
  • CUE N/A
  • RIBB N/A
  • Revenue Growth
  • CUE 69.16
  • RIBB N/A
  • 52 Week Low
  • CUE $0.45
  • RIBB $9.95
  • 52 Week High
  • CUE $2.26
  • RIBB $10.45
  • Technical
  • Relative Strength Index (RSI)
  • CUE 39.49
  • RIBB N/A
  • Support Level
  • CUE $0.72
  • RIBB N/A
  • Resistance Level
  • CUE $0.89
  • RIBB N/A
  • Average True Range (ATR)
  • CUE 0.10
  • RIBB 0.00
  • MACD
  • CUE 0.02
  • RIBB 0.00
  • Stochastic Oscillator
  • CUE 48.59
  • RIBB 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About RIBB RIBBON ACQUISITION CORP

Ribbon Acquisition Corp is a blank check company.

Share on Social Networks: